Pfizer Inc. (PFE)

NYSE: PFE · Real-Time Price · USD

24.17

-0.08 (-0.33%)

At close: Jul 10, 2026, 4:00 PM EDT

24.23

+0.06 (0.24%)

After-hours: Jul 10, 2026, 7:59 PM EDT

Revenue

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Primary Care Revenue	26.67B	26.82B	30.14B
Primary Care Revenue Growth	-0.57%	-11.00%	-2.16%
Specialty Care Revenue (Pre-FY2026 Reporting)	-	17.55B	16.65B
Specialty Care Revenue (Pre-FY2026 Reporting) Growth	-	5.37%	11.10%
Oncology Revenue (Pre-FY2026 Reporting)	-	16.83B	15.61B
Oncology Revenue (Pre-FY2026 Reporting) Growth	-	7.83%	25.40%
Global Pharmaceuticals Business (Biopharma) Revenue	61.92B	61.20B	62.40B
Global Pharmaceuticals Business (Biopharma) Revenue Growth	1.18%	-1.93%	7.15%
Business Innovation (Pfizer CentreOne) Revenue	1.37B	1.34B	1.15B
Business Innovation (Pfizer CentreOne) Revenue Growth	2.39%	16.75%	-9.91%
Revenue (Other)	25.00M	42.00M	81.00M
Revenue (Total)	63.32B	62.58B	63.63B
Revenue (Total) Growth	1.18%	-1.65%	6.84%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	37.44B	37.08B	38.69B
United States Revenue Growth	0.96%	-4.17%	37.47%
Developed Markets Revenue	16.44B	16.19B	16.06B
Developed Markets Revenue Growth	1.53%	0.82%	-23.21%
Emerging Markets Revenue	9.44B	9.31B	8.88B
Emerging Markets Revenue Growth	1.40%	4.89%	-15.42%
Revenue (Other)	1.00M	-	-
Revenue (Total)	63.32B	62.58B	63.63B
Revenue (Total) Growth	1.18%	-1.65%	6.84%

Revenue by Geography 2

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	37.44B	37.08B	38.69B
United States Revenue Growth	0.96%	-4.17%	37.47%
Revenue (Total)	63.32B	62.58B	63.63B
Revenue (Total) Growth	1.18%	-1.65%	6.84%

Revenue by Geography 3

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
United States Revenue	37.44B	37.08B	38.69B
United States Revenue Growth	0.96%	-4.17%	37.47%
International Revenue	25.88B	25.50B	24.94B
International Revenue Growth	1.48%	2.27%	-20.61%
Revenue (Total)	63.32B	62.58B	63.63B
Revenue (Total) Growth	1.18%	-1.65%	6.84%

EBT

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Global Pharmaceuticals Business (Biopharma) Earnings	29.08B	29.34B	27.97B
Global Pharmaceuticals Business (Biopharma) Earnings Growth	-0.91%	4.91%	77.39%
Other Business Activities Earnings	-8.45B	-8.20B	-7.21B

Key Performance Indicators

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar '26 Mar 29, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Comirnaty - Direct Sales and Alliance Revenue	4.04B	4.37B	5.35B
Comirnaty - Direct Sales and Alliance Revenue Growth	-7.60%	-18.42%	-52.29%
Eliquis - Direct Sales and Alliance Revenue	8.20B	7.96B	7.37B
Eliquis - Direct Sales and Alliance Revenue Growth	3.05%	8.08%	9.17%
Paxlovid Revenue	2.06B	2.36B	5.72B
Paxlovid Revenue Growth	-12.96%	-58.68%	346.91%
Prevnar Family Revenue	6.52B	6.49B	6.41B
Prevnar Family Revenue Growth	0.45%	1.29%	-1.38%
Nurtec ODT/Vydura Revenue	1.53B	1.42B	1.26B
Nurtec ODT/Vydura Revenue Growth	7.37%	12.75%	36.10%
Abrysvo Revenue	1.08B	1.03B	755.00M
Abrysvo Revenue Growth	4.84%	36.82%	-15.17%
Vyndaqel Family Revenue	6.50B	6.38B	5.45B
Vyndaqel Family Revenue Growth	1.82%	17.04%	64.14%
Xeljanz Revenue	1.14B	1.09B	1.17B
Xeljanz Revenue Growth	4.78%	-6.93%	-31.41%
Ibrance Revenue	4.15B	4.12B	4.37B
Ibrance Revenue Growth	0.78%	-5.61%	-8.12%